glucagon has been researched along with canagliflozin in 8 studies
| Studies (glucagon) | Trials (glucagon) | Recent Studies (post-2010) (glucagon) | Studies (canagliflozin) | Trials (canagliflozin) | Recent Studies (post-2010) (canagliflozin) |
|---|---|---|---|---|---|
| 26,039 | 1,498 | 3,054 | 998 | 194 | 975 |
| Protein | Taxonomy | glucagon (IC50) | canagliflozin (IC50) |
|---|---|---|---|
| Sodium/glucose cotransporter 1 | Homo sapiens (human) | 0.9497 | |
| Sodium/glucose cotransporter 2 | Homo sapiens (human) | 0.0039 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 6 (75.00) | 24.3611 |
| 2020's | 2 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Condren, AB; Donahue, EP; Farmer, TD; Healey, EC; Kim, K; McCoy, GA; O'Brien, TP; Printz, RL; Shiota, M; Ueta, K | 1 |
| Hara, K; Inukai, T; Naruse, R; Suetsugu, M; Takebayashi, K; Terasawa, T; Tsuchiya, T | 1 |
| Carria, LR; Cengiz, E; Patel, NS; Sherr, JL; Tamborlane, WV; Van Name, MA; Weinzimer, SA | 1 |
| Eckel, RH; Koh, KK; Lim, S | 1 |
| Kondo, Y; Mitsumatsu, T; Okahata, S; Sakamoto, K; Shiba, T; Tanaka, S | 1 |
| Kakizaki, S; Kikuchi, O; Kitamura, T; Kobayashi, M; Kohno, D; Matsui, S; Sasaki, T; Suga, T; Takeuchi, K; Wada, E; Yamada, M; Yokota-Hashimoto, H | 1 |
| Bojsen-Møller, KN; Dirksen, C; Fenger, M; Holst, JJ; Kristiansen, VB; Madsbad, S; Martinussen, C; Svane, MS; van Hall, G; Veedfald, S; Wewer Albrechtsen, NJ | 1 |
| Fushimi, Y; Hirukawa, H; Horiya, M; Iwamoto, Y; Kaku, K; Kan, Y; Kaneto, H; Kinoshita, T; Kohara, K; Mashiko, A; Mizoguchi-Tomita, A; Mune, T; Nakanishi, S; Nishioka, M; Obata, A; Okauchi, S; Sanada, J; Shimoda, M; Tatsumi, F | 1 |
1 review(s) available for glucagon and canagliflozin
| Article | Year |
|---|---|
Clinical implications of current cardiovascular outcome trials with sodium glucose cotransporter-2 (SGLT2) inhibitors.
Topics: Albuminuria; Atherosclerosis; Benzhydryl Compounds; Body Weight; Canagliflozin; Cardiovascular Diseases; Cardiovascular System; Glucagon; Glucagon-Like Peptides; Glucosides; Heart Failure; Hemodynamics; Humans; Hypoglycemic Agents; Ketones; Lipids; Liraglutide; Metabolic Syndrome; Metformin; Non-alcoholic Fatty Liver Disease; Osmosis; Risk Factors; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2018 |
3 trial(s) available for glucagon and canagliflozin
| Article | Year |
|---|---|
Effect of canagliflozin on circulating active GLP-1 levels in patients with type 2 diabetes: a randomized trial.
Topics: Aged; Blood Glucose; Canagliflozin; Diabetes Mellitus, Type 2; Female; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Insulin; Male; Middle Aged; Treatment Outcome | 2017 |
Mechanistic insights from sequential combination therapy with a sodium glucose co-transporter-2 inhibitor and a dipeptidyl peptidase-4 inhibitor: Results from the CANARIS Trial using canagliflozin and teneligliptin.
Topics: Adult; Aged; Blood Glucose; Canagliflozin; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Administration Schedule; Drug Therapy, Combination; Female; Glucagon; Humans; Hypoglycemic Agents; Insulin; Male; Middle Aged; Pyrazoles; Signal Transduction; Sodium-Glucose Transporter 2 Inhibitors; Thiazolidines | 2019 |
The effect of acute dual SGLT1/SGLT2 inhibition on incretin release and glucose metabolism after gastric bypass surgery.
Topics: Blood Glucose; C-Peptide; Canagliflozin; Cross-Over Studies; Gastric Bypass; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Glucose Tolerance Test; Humans; Incretins; Insulin; Middle Aged; Pancreatic Polypeptide; Sodium-Glucose Transporter 1; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2020 |
4 other study(ies) available for glucagon and canagliflozin
| Article | Year |
|---|---|
Glucotoxicity targets hepatic glucokinase in Zucker diabetic fatty rats, a model of type 2 diabetes associated with obesity.
Topics: Animals; Body Weight; Canagliflozin; Diabetes Mellitus, Type 2; Eating; Glucagon; Glucokinase; Glucose; Glucose Clamp Technique; Glucosides; Hyperglycemia; Hyperinsulinism; Immunohistochemistry; Liver; Male; Obesity; Organ Size; Oxygen Consumption; Rats; Rats, Zucker; RNA, Messenger; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2014 |
Altered Patterns of Early Metabolic Decompensation in Type 1 Diabetes During Treatment with a SGLT2 Inhibitor: An Insulin Pump Suspension Study.
Topics: Adolescent; Adult; Blood Glucose; Canagliflozin; Diabetes Mellitus, Type 1; Fatty Acids, Nonesterified; Female; Glucagon; Humans; Hypoglycemic Agents; Insulin; Insulin Infusion Systems; Male; Middle Aged; Sodium-Glucose Transporter 2 Inhibitors; Young Adult | 2017 |
SGLT1 in pancreatic α cells regulates glucagon secretion in mice, possibly explaining the distinct effects of SGLT2 inhibitors on plasma glucagon levels.
Topics: Animals; Benzhydryl Compounds; Blood Glucose; Canagliflozin; Diabetes Mellitus; Diet, High-Fat; Disease Models, Animal; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Glucagon-Secreting Cells; Glucose; Glucosides; Glycosuria; Hypoglycemic Agents; Insulin; Male; Mice; Mice, Inbred C57BL; Sodium-Glucose Transporter 1; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2019 |
Effect of Combination Therapy of Canagliflozin Added to Teneligliptin Monotherapy in Japanese Subjects with Type 2 Diabetes Mellitus: A Retrospective Study.
Topics: Aged; Blood Glucose; Canagliflozin; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Glucagon; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Japan; Male; Middle Aged; Pyrazoles; Retrospective Studies; Sodium-Glucose Transporter 2 Inhibitors; Thiazolidines; Treatment Outcome | 2020 |